This article is for premium subscribers. Please sign up here for a tax-deductible subscription.
If you're a premium subscriber, sign in below.
The state’s Prescription Drug Price Transparency Program was created to illuminate pharmaceutical pricing practices, but pharmaceutical companies have shielded information they say infringes on trade secrets.
The report, which failed to disclose conflicts of interest, advised against an effort by Medicare to recoup millions for discarded drugs.
Pharmacy benefit managers switched to virtual audits during the pandemic, which increased reviews, payment denials and their profits.
Ozempic’s peppy ads suggest that people who use it might lose weight, but also include a disclaimer: that it “is not a weight loss drug.” Now — as Wegovy — it is.
A Pfizer win in a lawsuit against the federal government could cost taxpayers billions of dollars and erase an important control on pharma marketing after decades of regulatory erosion and soaring drug prices, say health policy analysts.
Facing a host of challenges, Aduhelm’s makers are running an educational campaign directed at consumers who are worried about whether their forgetfulness is a sign of disease.
Reversing a trend in which contributions from drugmakers’ political committees and their employees have gone largely to Republicans, so far for 2020 the industry has tilted toward Democrats.
This article is for premium subscribers. Please sign up here for a tax-deductible subscription.
If you're a premium subscriber, sign in below.
Oregon lawmakers are considering changes to the state’s drug transparency law that would prevent pharmaceutical manufacturers from exploiting a potential loophole to avoid reporting price hikes and give state regulators more authority to expect timely information from drug companies.
This article is for premium subscribers. Please sign up here for a tax-deductible subscription.
If you're a premium subscriber, sign in below.
An Oregon program that aims to peel back the opaque layers of prescription drug pricing wrapped up its first year this week with a report to the Legislature that underlines
When a long, black bus bearing the logo of drugmaker AbbVie rolls through Washington state next year, it will promote a new effort to eradicate hepatitis C infections.
